Related Experiment Video
Updated: Jul 6, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Impact of rapamycin on liver regeneration
Daniel Palmes1, Andree Zibert, Tymotheus Budny
1Surgical Research, Department of General Surgery, Muenster University Hospital, Waldeyerstr. 1, 48149 Muenster, Germany.
Abstract:
The remarkable capacity of the liver to regenerate after injury and the prospects of organ self-renewal have attracted much interest in the understanding and modulation of the underlying molecular events. We investigated the effect of mammalian target of rapamycin (mTOR) inhibitor rapamycin (RAPA) on liver by correlating intravital microscopy, immunohistochemistry, and reverse transcriptase polymerase chain reaction in a rat model of 2/3 hepatectomy. RAPA significantly retarded proliferation of hepatocytes, endothelial cells, and hepatic stellate cells (HSCs) mostly between days 2 and 4 after hepatectomy and downregulated major cytokines and growth factors (tumor necrosis factor alpha, hepatocyte growth factor, platelet-derived growth factor, platelet-derived growth factor receptor, insulin-like growth factor-1, transforming growth factor beta 1) important for liver regeneration. These effects were almost absent at later time points. RAPA also had a transient, but broad effect on angiogenesis, and impaired sinusoidal density as well as mRNA levels of vascular endothelial growth factor, vascular endothelial growth factor receptor 1, vascular endothelial growth factor receptor 2, and angiopoietin-1. Activation of HSC was also transiently suppressed as observed by smooth muscle protein 1 alpha protein expression and intercellular adhesion molecule-1 mRNA levels. The rate of apoptosis in liver was significantly increased by RAPA between day 3 and day 7. The effect of RAPA on liver repair, angiogenesis, and HSC activation is confined to the phase of active cell proliferation. This transient effect might allow further exploration of mTOR inhibitors in clinical situations that involve liver regeneration, and seems to have implications beyond immunosuppression.
Insights
Rapamycin (RAPA), an mTOR inhibitor, transiently suppresses liver regeneration by inhibiting cell proliferation and angiogenesis. Its effects are limited to the active regeneration phase, suggesting potential therapeutic applications.
Area of Science:
- Hepatology
- Molecular Biology
- Regenerative Medicine
Background:
- The liver's regenerative capacity is crucial for organ self-renewal after injury.
- Understanding the molecular mechanisms of liver regeneration is key for therapeutic interventions.
Purpose of the Study:
- To investigate the effect of mammalian target of rapamycin (mTOR) inhibitor rapamycin (RAPA) on liver regeneration.
- To elucidate the impact of RAPA on cellular proliferation, angiogenesis, and hepatic stellate cell (HSC) activation.
Main Methods:
- Utilized a rat model of 2/3 hepatectomy.
- Employed intravital microscopy, immunohistochemistry, and reverse transcriptase polymerase chain reaction (RT-PCR).
Main Results:
- RAPA significantly retarded proliferation of hepatocytes, endothelial cells, and HSCs between days 2-4 post-hepatectomy.
- Downregulated key cytokines and growth factors (e.g., TNF-α, HGF, PDGF, IGF-1, TGF-β1) essential for liver regeneration.
- Transiently impaired angiogenesis and HSC activation, while increasing apoptosis between days 3-7.
Conclusions:
- The effects of RAPA on liver repair, angiogenesis, and HSC activation are confined to the active cell proliferation phase.
- This transient effect suggests potential clinical applications for mTOR inhibitors in liver regeneration beyond immunosuppression.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...

